Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN Balis, F., Green, D. M., Anderson, C., Cook, S., Dhillon, J., Gow, K., Hiniker, S., Jasty-Rao, R., Lin, C., Lovvorn, H., MacEwan, I., Martinez-Agosto, J., Mullen, E., Murphy, E. S., Ranalli, M., Rhee, D., Rokitka, D., Tracy, E. L., Vern-Gross, T., Walsh, M. F., Walz, A., Wickiser, J., Zapala, M., Berardi, R. A., Hughes, M. 2021; 19 (8): 945-977

Abstract

The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.

View details for DOI 10.6004/jnccn.2021.0037

View details for PubMedID 34416707